vs
Side-by-side financial comparison of Hologic (HOLX) and KB HOME (KBH). Click either name above to swap in a different company.
KB HOME is the larger business by last-quarter revenue ($1.7B vs $1.0B, roughly 1.6× Hologic). Hologic runs the higher net margin — 17.1% vs 6.0%, a 11.1% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -15.3%). KB HOME produced more free cash flow last quarter ($290.1M vs $215.2M). Over the past eight quarters, KB HOME's revenue compounded faster (7.4% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
KB Home is an American homebuilding company founded in 1957 as Kaufman & Broad in Detroit, Michigan. It was the first company to be traded on the New York Stock Exchange as a home builder. Its headquarters are in Los Angeles, California.
HOLX vs KBH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.7B |
| Net Profit | $179.1M | $101.5M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | — |
| Net Margin | 17.1% | 6.0% |
| Revenue YoY | 2.5% | -15.3% |
| Net Profit YoY | -10.9% | -46.7% |
| EPS (diluted) | $0.79 | $1.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.7B | ||
| Q3 25 | $1.0B | $1.6B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.0B | $2.0B | ||
| Q3 24 | $988.0M | $1.8B | ||
| Q2 24 | $1.0B | $1.7B | ||
| Q1 24 | $1.0B | $1.5B |
| Q4 25 | $179.1M | $101.5M | ||
| Q3 25 | $187.2M | $109.8M | ||
| Q2 25 | $194.9M | $107.9M | ||
| Q1 25 | $-17.4M | $109.6M | ||
| Q4 24 | $201.0M | $190.6M | ||
| Q3 24 | $178.6M | $157.3M | ||
| Q2 24 | $194.5M | $168.4M | ||
| Q1 24 | $169.9M | $138.7M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | — | ||
| Q3 25 | 22.6% | — | ||
| Q2 25 | 24.9% | — | ||
| Q1 25 | -0.7% | — | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 23.3% | — | ||
| Q2 24 | 24.1% | — | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 17.1% | 6.0% | ||
| Q3 25 | 17.8% | 6.8% | ||
| Q2 25 | 19.0% | 7.1% | ||
| Q1 25 | -1.7% | 7.9% | ||
| Q4 24 | 19.7% | 9.5% | ||
| Q3 24 | 18.1% | 9.0% | ||
| Q2 24 | 19.2% | 9.9% | ||
| Q1 24 | 16.7% | 9.4% |
| Q4 25 | $0.79 | $1.55 | ||
| Q3 25 | $0.84 | $1.61 | ||
| Q2 25 | $0.86 | $1.50 | ||
| Q1 25 | $-0.08 | $1.49 | ||
| Q4 24 | $0.87 | $2.50 | ||
| Q3 24 | $0.75 | $2.04 | ||
| Q2 24 | $0.82 | $2.15 | ||
| Q1 24 | $0.72 | $1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | — |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $3.9B |
| Total Assets | $9.2B | $6.7B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $3.9B | ||
| Q3 25 | $5.0B | $3.9B | ||
| Q2 25 | $4.8B | $4.0B | ||
| Q1 25 | $4.6B | $4.1B | ||
| Q4 24 | $4.8B | $4.1B | ||
| Q3 24 | $5.1B | $4.0B | ||
| Q2 24 | $5.0B | $4.0B | ||
| Q1 24 | $4.8B | $3.9B |
| Q4 25 | $9.2B | $6.7B | ||
| Q3 25 | $9.0B | $7.0B | ||
| Q2 25 | $8.8B | $7.0B | ||
| Q1 25 | $8.5B | $7.0B | ||
| Q4 24 | $8.7B | $6.9B | ||
| Q3 24 | $9.2B | $6.8B | ||
| Q2 24 | $8.9B | $6.8B | ||
| Q1 24 | $8.7B | $6.7B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $303.8M |
| Free Cash FlowOCF − Capex | $215.2M | $290.1M |
| FCF MarginFCF / Revenue | 20.5% | 17.1% |
| Capex IntensityCapex / Revenue | 1.4% | 0.8% |
| Cash ConversionOCF / Net Profit | 1.28× | 2.99× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $287.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $303.8M | ||
| Q3 25 | $355.1M | $197.7M | ||
| Q2 25 | $343.3M | $168.4M | ||
| Q1 25 | $169.4M | $-334.3M | ||
| Q4 24 | $189.3M | $362.6M | ||
| Q3 24 | $367.0M | $-89.9M | ||
| Q2 24 | $405.8M | $61.5M | ||
| Q1 24 | $292.4M | $28.5M |
| Q4 25 | $215.2M | $290.1M | ||
| Q3 25 | $341.4M | $185.8M | ||
| Q2 25 | $330.5M | $156.9M | ||
| Q1 25 | $153.9M | $-345.5M | ||
| Q4 24 | $172.5M | $352.6M | ||
| Q3 24 | $350.6M | $-99.4M | ||
| Q2 24 | $385.3M | $51.2M | ||
| Q1 24 | $279.6M | $19.1M |
| Q4 25 | 20.5% | 17.1% | ||
| Q3 25 | 32.5% | 11.5% | ||
| Q2 25 | 32.3% | 10.3% | ||
| Q1 25 | 15.3% | -24.8% | ||
| Q4 24 | 16.9% | 17.6% | ||
| Q3 24 | 35.5% | -5.7% | ||
| Q2 24 | 38.1% | 3.0% | ||
| Q1 24 | 27.5% | 1.3% |
| Q4 25 | 1.4% | 0.8% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 1.3% | 0.8% | ||
| Q1 25 | 1.5% | 0.8% | ||
| Q4 24 | 1.6% | 0.5% | ||
| Q3 24 | 1.7% | 0.5% | ||
| Q2 24 | 2.0% | 0.6% | ||
| Q1 24 | 1.3% | 0.6% |
| Q4 25 | 1.28× | 2.99× | ||
| Q3 25 | 1.90× | 1.80× | ||
| Q2 25 | 1.76× | 1.56× | ||
| Q1 25 | — | -3.05× | ||
| Q4 24 | 0.94× | 1.90× | ||
| Q3 24 | 2.05× | -0.57× | ||
| Q2 24 | 2.09× | 0.37× | ||
| Q1 24 | 1.72× | 0.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
KBH
| Home Building | $1.7B | 99% |
| Financial Service | $8.7M | 1% |
